Cencora Inc. Common Stock (COR)
Stock · NYSE · Health Care
$322.02as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$313.35
Industry
Other Pharmaceuticals
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical c…
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- Employees
- 47,000
- Website
- www.cencora.com/
Fundamentals
- 1-day range
- $320.39$323.74
- Market cap
- $63.23B
- P/E (trailing)
- 22.54
- P/E (forward)
- 16.27
- EPS (trailing)
- $13.45
- Dividend yield
- 1.01%
- Beta
- 0.57
- Avg. volume
- 1.47M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- August 31, 2026
52-week range
$244.82$377.54
Next earnings: November 4, 2026 · EPS estimate $4.54After Closeconfirmed
How Cencora Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 25, 2025 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Buy 75%
Hold 25%
Sell 0%
1-year price forecast
High
$430
+33.5%
Median
$370
+14.9%
Low
$330
+2.5%
Cencora Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CORCencora Inc. Common Stock$322.02▲ 0.25%Market cap $63.23BP/E 22.54$244.82$377.54
- MCKMcKesson Corporation Common Stock$894.35▲ 0.43%Market cap $104.74BP/E 21.89$677.28$999
- HLFHerbalife Ltd. Common Shares$12.43▲ 0.65%Market cap $1.19BP/E 7.68$7.56$20.4
- ZSTKZeroStack Corp. Common Stock$5.51▼ 6.29%Market cap $30.78MP/E —$1.32$47
- HKPDCellyan Biotechnology Co. Ltd Class A Ordinary Shares$0.36▼ 11.33%Market cap $16.93MP/E —$0.31$1.82
- SNYRSynergy CHC Corp. Common Stock$0.1001▼ 4.67%Market cap $2.44MP/E —$0.087$3.59
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COR Cencora Inc. Common Stock | $63.23B | 22.54 | $322.02 | ▲ 0.25% | $244.82$377.54 |
| MCK McKesson Corporation Common Stock | $104.74B | 21.89 | $894.35 | ▲ 0.43% | $677.28$999 |
| HLF Herbalife Ltd. Common Shares | $1.19B | 7.68 | $12.43 | ▲ 0.65% | $7.56$20.4 |
| ZSTK ZeroStack Corp. Common Stock | $30.78M | — | $5.51 | ▼ 6.29% | $1.32$47 |
| HKPD Cellyan Biotechnology Co. Ltd Class A Ordinary Shares | $16.93M | — | $0.36 | ▼ 11.33% | $0.31$1.82 |
| SNYR Synergy CHC Corp. Common Stock | $2.44M | — | $0.1001 | ▼ 4.67% | $0.087$3.59 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Walmart Agrees to $50 Million Settlement With DOJ Over Alleged Opioid Prescription Violations, Calls Payout ‘Immaterial’benzinga · 8/29/2026
- Walmart Agrees to $50 Million Settlement With DOJ Over Alleged Opioid Prescription Violations, Calls Payout ‘Immaterial’Benzinga · 8/29/2026
- Elizabeth S Campbell Takes Money Off The Table, Sells $3.66M In Cencora StockBenzinga · 8/26/2026
- Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio PerformanceSeekingAlpha · 8/23/2026
- Dividend Champion, Contender, And Challenger Highlights: Week August 23SeekingAlpha · 8/21/2026
- RBC Capital Initiates Coverage of Cencora (COR) with Sector Perform RecommendationFintel · 8/20/2026
- $100 Invested In Cencora 10 Years Ago Would Be Worth This Much TodayBenzinga · 8/19/2026
- RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330Benzinga · 8/19/2026
- Artisan Global Opportunities Fund Q2 2026 Portfolio ReviewSeekingAlpha · 8/19/2026
Insider Activity
Insider Actions →Acquired
25.8K
Disposed
16.7K
- Elizabeth S. Campbell · August 24, 2026 · Sale11.3K @ $324.12
- Lauren M. Tyler · July 31, 2026 · Grant97 @ $311.34
- Dennis M. Nally · July 31, 2026 · Grant113 @ $311.34
- Ellen Cooper · July 31, 2026 · Grant97 @ $311.34
- Elizabeth S. Campbell · June 30, 2026 · Grant50 @ $240.53
- Silvana Battaglia · June 30, 2026 · Grant58 @ $240.53
- Lauren M. Tyler · June 22, 2026 · Buy550 @ $270.23
- Dermot Mark Durcan · June 18, 2026 · Buy4.0K @ $274.19
- Dermot Mark Durcan · May 28, 2026 · Buy4.0K @ $266.26
- Lauren M. Tyler · May 1, 2026 · Grant99 @ $304
- Dennis M. Nally · May 1, 2026 · Grant116 @ $304
- Ellen Cooper · May 1, 2026 · Grant99 @ $304
- Lazarus Krikorian · April 1, 2026 · Grant3.9K
- James F. Cleary · March 11, 2026 · Option Exercise12.6K
- James F. Cleary · March 11, 2026 · Tax Withholding5.4K @ $350.3
Institutional Ownership
March 31, 2026
- Total shares held
- 165.00M
- Total value held
- $45.92B
- Institutional holders
- 1413
Top holders this quarter
- Unknown19.94M
- Unknown9.59M
- Unknown9.19M
- Unknown7.32M
- Unknown6.69M
- Unknown6.29M
- Unknown5.57M
- Unknown4.55M
- Unknown4.53M
- Unknown4.48M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
Insider Sale and Opioid Settlement Headlines Surface for Cencora. Cencora has drawn recent attention from two unrelated developments. An insider sold about $3.66 million worth of company stock, a routine disclosure that can sometimes raise questions among investors. Separately, a $50 million DOJ settlement involving opioid prescription practices at a major retailer was reported, calling the payout immaterial to that company's finances, with no direct link stated to Cencora's distribution business. The drug distribution industry has faced heightened legal scrutiny around opioid handling in past years, which is the broader context in which such headlines are read. Fundamentals context only: shares trade near the middle of their 52-week range with a P/E of 22.5.